Cited by

• Characterization of genetic variation and natural selection at the arylamine N-acetyltransferase genes in global human populations.

  Mortensen HM, Froment A, Lema G, Bodo JM, Ibrahim M, Nyambo TB, Omar SA, Tishkoff SA. Mortensen HM, et al. Pharmacogenomics. 2011 Nov;12(11):1545-58. doi: 10.2217/pgs.11.88. Epub 2011 Oct 13. Pharmacogenomics. 2011. PMID: 21995608 Free PMC article.
• Genotyping of the arylamine N-acetyltransferase polymorphism in the prediction of idiosyncratic reactions to trimethoprim-sulfamethoxazole in infants.

  Zielińska E, Niewiarowski W, Bodalski J, Rebowski G, Skretkowicz J, Mianowska K, Sekulska M. Zielińska E, et al. Pharm World Sci. 1998 Jun;20(3):123-30. doi: 10.1023/a:1008664707825. Pharm World Sci. 1998. PMID: 9618736 Clinical Trial.
• Arylamine N-acetyltransferase in Balb/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro.

  Kelly SL, Sim E. Kelly SL, et al. Biochem J. 1994 Sep 1;302 ( Pt 2)(Pt 2):347-53. doi: 10.1042/bj3020347. Biochem J. 1994. PMID: 7545952 Free PMC article.
• Pharmacogenetics of cancer therapy: getting personal.

  Krynetski EY, Evans WE. Krynetski EY, et al. Am J Hum Genet. 1998 Jul;63(1):11-6. doi: 10.1086/301941. Am J Hum Genet. 1998. PMID: 9634537 Free PMC article. Review. No abstract available.
• Pharmacokinetics of a novel N-methyl-D-aspartate receptor antagonist (SM-18400): identification of an N-acetylated metabolite and pre-clinical assessment of N-acetylation polymorphism.

  Yabuki M, Kon-Ya Y, Kataoka M, Shimizudani T, Akao K, Ito M, Kanamaru H, Nakatsuka I. Yabuki M, et al. Eur J Drug Metab Pharmacokinet. 2003 Jan-Mar;28(1):21-9. doi: 10.1007/BF03190863. Eur J Drug Metab Pharmacokinet. 2003. PMID: 14503661